Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.-MedSci.cn

Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.

Dohner, H; Wei, A; Montesinos, P; Dombret, H; Ravandi, F; Sayar, H; Porkka, K; Sandhu, I; Passamonti, F; Pane, F; Robak, T; Falantes, JF; Schuh, AC; Ossenkoppele, GJ; La Torre, I; Skikne, B; Kumar, K; Dong, Q; Beach, CL; Roboz, GJ

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (15):

科室
- - 订阅+
  - 更多科室
工具
服务